Should You Buy Bayer Stock in 2026? Full Analysis
Wondering whether to buy Bayer stock? The German life sciences group — pharmaceuticals, consumer health and agriculture — trades at a discounted valuation and carries high legal risk inherited from its acquisition of Monsanto. This profile reviews Bayer’s earnings, dividend, strengths, risks and how to buy the stock, to help you answer the question for yourself.
Bayer Stock Price
The stock is listed in Frankfurt (BAYN) and trades as an over-the-counter ADR in the United States (BAYRY). Live quotes are available from your broker or on leading financial platforms; the share price has fallen sharply from its highs before the Monsanto acquisition, reflecting the market’s lingering doubts about the litigation and the debt.
Market Data and History, Updated Automatically
BAYN.DE · XETRA| Exercice clos le | Chiffre d’affaires | Résultat net |
|---|---|---|
| 2025-12-31 | 45,58 Md € | -3,62 Md € |
| 2024-12-31 | 46,61 Md € | -2,55 Md € |
| 2023-12-31 | 47,64 Md € | -2,94 Md € |
| 2022-12-31 | 50,74 Md € | 4,15 Md € |
| Date de détachement | Montant par action |
|---|---|
| 2026-04-27 | 0,110 € |
| 2025-04-28 | 0,110 € |
| 2024-04-29 | 0,110 € |
| 2023-05-02 | 2,400 € |
| 2022-05-02 | 2,000 € |
Source: Yahoo Finance, data collected by the server (collection date shown under each block). Indicative data only; does not constitute investment advice.
Bayer Stock Profile
| Company | Bayer Aktiengesellschaft |
| Market | XETRA Frankfurt (BAYN); OTC ADR New York (BAYRY) (checked on 10/27/2026) |
| Ticker | BAYN (Frankfurt) · BAYRY (ADR) |
| ISIN | DE000BAY0017 |
| Headquarters | Leverkusen (North Rhine-Westphalia), Germany |
| Sector | Life sciences: pharmaceuticals, consumer health, crop science |
| Trading currency | Euro (EUR); accounts reported in euros |
| Financial year end | December 31 |
| PEA eligibility | Yes (German issuer headquartered in the European Union) |
About Bayer: Business and Markets
Three Divisions, One Life Sciences Group
Founded in 1863 and led since 2024 by William Anderson, Bayer employs around 88,000 people across three pillars: pharmaceuticals (cardiology, ophthalmology, oncology), consumer health (over-the-counter and self-care medicines) and crop science (seeds and crop protection). Aspirin, invented by the group, symbolizes an industrial history spanning more than 160 years.
The Monsanto Legacy, a Legal Burden
The 2018 acquisition of Monsanto for around $63 billion gave Bayer its agricultural portfolio — but also the litigation over the Roundup weedkiller and glyphosate, as well as PCBs and Dicamba, brought before US courts. Successive provisions, payouts and judgments have pushed the accounts into a net loss since 2023 and fuel the stock’s discount: this is the key issue to follow before buying.
A Strategic Overhaul Under Way
The new management has launched a plan to simplify the organization and cut costs — pushing decisions down, removing management layers and selling non-core assets — aimed at restoring margins and free cash flow. A possible separation of divisions is still being debated; check the latest published reports for the actual status of this project.
Bayer Earnings and Financial Data
Consolidated accounts for the last three financial years ended December 31:
| Metric | FY 2023 | FY 2024 | FY 2025 | Year-on-year change |
|---|---|---|---|---|
| Revenue | €47,637M | €46,606M | €45,575M | -2.2% |
| Net income | -€2,941M | -€2,552M | -€3,620M | wider loss |
Amounts in millions of euros. Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data accessed on 10/27/2026.
The table sums up the paradox of this stock: massive revenue that is slowly eroding under competitive pressure in agriculture, and repeated net losses largely due to legal charges and impairments in the crop science division. The gap between these accounting losses and operating cash generation is at the heart of the investment debate on Bayer: check the latest published reports for details on provisions and cash flow.
Bayer Stock Dividend
Historically generous, the dividend has been cut to the bare minimum over the course of the crisis: €0.11 per share for the 2024 financial year, a token amount kept for legal and financial prudence. The board reviews the payout policy every year; investors should not buy Bayer for its current yield, but for a possible future normalization of payouts if the litigation is resolved.
Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →Should You Buy Bayer Stock in 2026?
Strengths:
- Very low valuation: the market prices in a deep discount for legal risk and debt.
- High-quality industrial assets: strong pharmaceutical and consumer health franchises, and a global leader in agriculture.
- Cost-cutting and simplification plan under way, with free cash flow gradually being rebuilt.
Points to watch:
- Roundup/Dicamba/PCB litigation: number of claims and final cost still uncertain after years of proceedings.
- High debt inherited from the Monsanto acquisition, in an environment of more expensive long-term interest rates.
- Revenue down for three years in a row: competitive pressure on seeds and crop protection.
- Residual dividend: no meaningful income while waiting for an uncertain normalization.
So, should you buy? Bayer is a high-risk turnaround play: suitable for a patient investor who accepts an unpredictable legal outcome, it is not suitable for cautious investors or an income strategy. The position should remain small within a diversified portfolio, with a staggered entry.
Fundamental and Technical Analysis of Bayer Stock
Fundamental Analysis
Three indicators drive the investment case: the free cash flow trajectory against the debt maturity schedule, changes in legal provisions and related payouts, and operating margin by division as the restructuring plan takes effect. The forward valuation multiple — around ten times expected earnings according to market data compiled by StockAnalysis — shows that the market remains very cautious.
Technical Analysis
The stock has doubled from its lows before consolidating: a typical profile for a stock in recovery, with large swings around court verdicts and annual results. Long-term moving averages and psychological levels are the usual reference points; our technical analysis guide explains these tools in detail.
How to Buy Bayer Stock
- Choose a broker that offers access to the Frankfurt Stock Exchange — compare fees in our selection of the best online brokers.
- Open a PEA if you wish: as a German issuer, Bayer is eligible for the PEA as well as an ordinary securities account.
- Fund your account: the stock trades in euros in Frankfurt, with no currency conversion fees.
- Place your order on the BAYN ticker, preferably as a limit order; the full method is explained in our guide on how to buy stocks.
Trading Hours
XETRA continuous trading runs from 9:00 a.m. to 5:30 p.m. Central European Time: no time difference from Paris. The BAYRY ADR trades over the counter in the United States with lower liquidity: favor the European listing.
Taxation
German dividends are subject to local withholding tax, and the excess can be reclaimed under the France-Germany tax treaty; capital gains fall under the French tax regime (30% flat tax in a securities account, income tax exemption after five years in a PEA).
FAQ About Bayer Stock
Should you buy Bayer stock in 2026?
It depends on your tolerance for legal risk: the stock offers a deep discount in exchange for unresolved Roundup litigation and heavy debt. It is aimed at patient investors, as a small, staggered position, and never as a safe haven.
Can you hold Bayer stock in a PEA?
Yes. As a German company listed in the European Union, Bayer is eligible for the PEA as well as an ordinary securities account — a rare advantage among major European pharma companies outside France.
What is the status of the Roundup litigation?
US proceedings are continuing after several years of settlements and conflicting verdicts; the final cost has not been determined. Check the latest published reports for current provisions.
Does Bayer pay a dividend?
Yes, but at a token level: €0.11 per share for 2024, a policy reviewed each year based on the company’s financial and legal situation.
What were Bayer’s 2025 results?
Revenue of €45.6 billion (down 2.2%) and a net loss of €3.6 billion, according to the consolidated accounts.
Disclaimer: this content is for information purposes only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not indicative of future results.
